FMP

FMP

Enter

LEXX - Lexaria Bioscience C...

photo-url-https://images.financialmodelingprep.com/symbol/LEXX.png

Lexaria Bioscience Corp.

LEXX

NASDAQ

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

1.21 USD

-0.025 (-2.07%)

LEXX Financial Statements

Year

2024

2023

2022

2021

Total Revenue

464.28k

226.21k

255.4k

722.74k

Cost of Revenue

4.82k

31.5k

71.84k

175.35k

Gross Profit

459.46k

194.71k

183.56k

547.39k

Operating Expenses

6.21M

6.73M

7.57M

6.23M

Research and Development

2.36M

3.67M

1.84M

1.26M

Selling, General & Administrative Expenses

3.85M

3.06M

5.72M

4.97M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

3.85M

3.06M

5.72M

4.97M

Other Expenses

0

0

0

0

Operating Income

-5.75M

-6.53M

-7.38M

-5.69M

Total Other Income/Expenses Net

-55.52k

-178.5k

-764.61k

1.52M

Income Before Tax

-5.81M

-6.71M

-7.38M

-4.16M

Income Tax

0

0

-114.33k

-1.66M

Net Income

-5.8M

-6.66M

-7.27M

-2.5M

Basic EPS

-0.47

-1.01

-1.24

-0.57

EPS Diluted

-0.47

-1.01

-1.24

-0.57

Basic Average Shares

12.38M

6.61M

5.89M

4.39M

Diluted Average Shares

12.38M

6.61M

5.89M

4.39M

EBITDA

-5.68M

-6.39M

-6.52M

-5.58M

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

-45.76M

-39.1M

-31.83M

-27.8M

Net Income

-5.8M

-6.66M

-7.27M

-2.5M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-51.56M

-45.76M

-39.1M

-31.83M

Other Distributions

-5.8M

-6.66M

-7.27M

-4.03M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

389.55k

421.59k

367.95k

459.25k

Annual Depreciation

76.15k

145.4k

146.91k

147.6k

Capital Expenditure

-43.02k

-169.61k

-131.45k

-79.49k

Net PPE

356.42k

445.8k

352.48k

391.15k

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep